von Willebrand factor: an emerging target in stroke therapy. - Wikidata - wikimedia - TriplyDB

von Willebrand factor: an emerging target in stroke therapy.

von Willebrand factor: an emerging target in stroke therapy.

http://www.wikidata.org/entity/Q33915674

about

Animal models for thrombotic thrombocytopenic purpura ROCKs as immunomodulators of stroke Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'Genetic Drivers of von Willebrand Factor Levels in an Ischemic Stroke Population and Association With Risk for Recurrent Stroke.The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitus Increased morbidity during long-term follow-up of survivors of thrombotic thrombocytopenic purpura.High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion.Regulation of VWF expression, and secretion in health and disease.Thrombosis: tangled up in NETs.Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study.Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease.von Willebrand factor, Jedi knight of the bloodstream G protein-dependent basal and evoked endothelial cell vWF secretion.Case-control study of platelet glycoprotein receptor Ib and IIb/IIIa expression in patients with acute and chronic cerebrovascular disease.Prothrombotic risk factors and antithrombotic therapy in children with ischemic stroke A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury.Extracellular chromatin is an important mediator of ischemic stroke in mice.Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice.Discs large 1 (Dlg1) scaffolding protein participates with clathrin and adaptator protein complex 1 (AP-1) in forming Weibel-Palade bodies of endothelial cells.Von Willebrand Factor Abnormalities Studied in the Mouse Model: What We Learned about VWF Functions.Synergistic Effect of AJW200, a von Willebrand Factor Neutralizing Antibody with Low Dose (0.9 mg/mg) Thrombolytic Therapy Following Embolic Stroke in Rabbits von Willebrand factor: the old, the new and the unknown.Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk.cAMP signalling in the vasculature: the role of Epac (exchange protein directly activated by cAMP).Of von Willebrand factor and platelets.Review And Insights Into The Bleeding Mechanism Incited By Antithrombotic Therapy: Mechanistic Nuances Of Dual Pro-Hemorrhagic Substrate Incorporating Drug-Induced Microvascular Leakage.Thrombosis and von Willebrand Factor.No risk, no benefit: still true for antithrombotic stroke treatments?Prenatal stress-induced increases in hippocampal von Willebrand factor expression are prevented by concurrent prenatal escitalopram.Assessment of the Diagnostic Value of Plasma Levels, Activities, and Their Ratios of von Willebrand Factor and ADAMTS13 in Patients with Cerebral Infarction.An Integrative Thrombosis Network: Visualization and Topological Analysis.TRPM4 inhibition promotes angiogenesis after ischemic stroke.Interaction between vWF levels and aspirin resistance in ischemic stroke patients.Discovery and Longitudinal Evaluation of Candidate Biomarkers for Ischaemic Stroke by Mass Spectrometry-Based Proteomics.Von Willebrand factor protects against acute CCl4-induced hepatotoxicity through phospho-p38 MAPK signaling pathway inhibition.New insights into the non-hemostatic role of von Willebrand factor in endothelial protection.ADAMTS-13 and von Willebrand factor: a dynamic duo.Elevated Factor VIII and von Willebrand Factor Levels Predict Unfavorable Outcome in Stroke Patients Treated with Intravenous Thrombolysis.Von Willebrand factor deficiency reduces liver fibrosis in mice.Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage.

P2860

Q26851228-862D6579-3B28-4F5C-8B22-5C76B2BEBDA9 Q26853214-DB99A2F6-F153-4A98-B237-3C157C5167A8 Q26865345-A279F6AF-E6AD-4447-B081-44DDBA114335 Q30252447-C2176AC1-B962-48B4-9B9B-0433F2DE3CB6 Q33405692-A3DBACA6-1ED3-40B0-BDBE-1C9D6B56F64A Q33424847-84769840-0EF4-4141-8EA1-3A79B0B22133 Q33427429-B7301EFE-EEF7-4E7D-A09C-650B2DDE47F1 Q33429209-360E7242-6085-4EAC-8A93-AC2143994DB7 Q33556910-A72D1F73-2388-42D9-9A41-272A0374EA72 Q33768997-4764683C-B17B-4241-9522-13BC55FDDF86 Q33773324-E4EA0F13-D87C-4CC4-9FB6-005A425AA26D Q34106824-73C17160-5F88-4EFE-9858-EA93E77F2E69 Q35003012-7AE77162-C612-463C-BB42-048910A7B2EB Q35154663-B0397358-4444-4338-ADBC-55F83D7E595F Q35168617-FC323867-733A-40CF-85DE-D4CD5AD0F666 Q35911764-6D41CD21-AC5E-43E7-B63D-C8E0E34F703F Q36387981-9F591C44-FA79-48D0-9C22-F0E342DF54C6 Q36509653-31D04320-3AA5-484C-AD5D-80837074F719 Q36812481-D5704600-4490-4E7A-BA35-181F3AD0A4B9 Q37078881-5B5B07A3-104F-40C4-A532-1905547DF0C2 Q37284566-0AD14AF6-B785-404F-9472-AF08A5C6EB35 Q38047344-7E5A6859-45E2-46FC-B847-58D694A9848E Q38058760-64B966BE-A495-43B4-BA66-4273CF6EF797 Q38180763-098541B3-1FD5-4F2A-BC31-E98B31D68E62 Q38258281-E038A3A0-ECD0-45DF-9851-36A9391BF22A Q39037122-D036B630-18BA-4038-BF3D-6FBF0BC6E079 Q39390612-070DB2FA-1496-4475-9C6A-481AE31DBBEB Q39451169-2F44A179-22B6-465F-828A-0855D0AF4C97 Q39596644-929D7DBC-020F-4B6D-B693-AB47DB57B6F5 Q41008620-5600962A-CDB0-4E2D-AB79-762535DEB617 Q41444600-04384EF1-ABFE-4306-88A9-D4CE20FBA06C Q44770508-17F10CF8-CF56-4D14-8E91-A174C64A1A7F Q46108183-430DF617-4BD4-45BF-8533-9363BF12170A Q47159530-658987D0-1137-4240-A320-201860876F02 Q47861398-BE72856F-2D41-4788-A8DE-6378512DCBB8 Q48719553-79E8A210-7639-4992-BC4E-C1FE6F46DECF Q50135856-F660636F-20AB-418A-B4F3-7E9DD25EAE5F Q50147547-21E98B55-C508-4BF8-AEA1-4E10E0B25F82 Q50206717-07E24053-D6E4-4EC3-9EC1-C5CA77FD5153 Q52108061-4A07F2CC-D16A-43ED-B26B-B685A539B6F7

P2860

von Willebrand factor: an emerging target in stroke therapy.

http://www.wikidata.org/entity/Q33915674

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

von Willebrand factor: an emerging target in stroke therapy.

@ast

von Willebrand factor: an emerging target in stroke therapy.

@en

type

label

von Willebrand factor: an emerging target in stroke therapy.

@ast

von Willebrand factor: an emerging target in stroke therapy.

@en

prefLabel

von Willebrand factor: an emerging target in stroke therapy.

@ast

von Willebrand factor: an emerging target in stroke therapy.

@en

P1433

Q33915674-68A36C7E-DB47-4D2C-9F6F-2BBC7DCBD0F5

P1476

Q33915674-1E51184E-CE13-4E07-9C52-3923BEC970BB

P2093

Q33915674-20F63850-CB15-4F96-BC25-AE508EC0F3F6

Q33915674-9DF0253D-014E-4F6A-A377-ABCE58CE170F

Q33915674-A21E3BF3-77D1-4528-BCDF-3ED7431CA910

P2860

Q33915674-026FD573-E2CA-47FA-85F1-FD9CA47CAB34

Q33915674-09EE1916-1467-4C24-8333-722B254A419F

Q33915674-0DCD4551-6BB0-4BFC-9972-EB5CD4D861DA

Q33915674-11C5F6B2-0C2E-4E6F-B100-3A6019BF38BB

Q33915674-1508F4F5-EAD1-4BF6-B459-A26A3F3559AA

Q33915674-1903E743-104D-426B-91B5-D3EF5A8821BD

Q33915674-1EE5016B-A218-4563-96E0-47A2007ACE5E

Q33915674-271F489B-58C1-481C-B84B-6E8D4FA0284D

Q33915674-277135E6-4BF7-4EA3-8B80-1873B755AF54

Q33915674-3B0C338A-8417-423F-A413-D6A4A322406E

P304

Q33915674-D85B8EB8-26E8-48C5-9B9A-EB2FBE78FE12

P31

Q33915674-816C3173-C70D-4143-B067-B3A6D027022E

P356

Q33915674-8570EFB9-A297-4CE2-B067-9AB6DCB6C5AE

P407

Q33915674-A2DF99F4-5059-48D5-83B3-A1A91B45E511

P433

Q33915674-EB472C26-6D80-478E-B4A4-7B42866B6662

P478

Q33915674-0E4F39AE-AA9F-42F6-8D60-17F6DC0FAF36

P50

Q33915674-F4280C6E-7BCB-407A-8210-F7C160586291

P577

Q33915674-7B0239D0-85B2-4BEB-9B01-278439684877

P5875

Q33915674-1A6B200E-CDB3-4176-8E52-6A899103C693

P698

Q33915674-9407E278-971C-42B7-85D6-0F77A4EF848D

P932

Q33915674-176EE3EC-57D6-4AE8-B60A-0FCC290F1902

P356

STROKEAHA.111.628867

P1433

P1476

von Willebrand factor: an emerging target in stroke therapy

@en

P2093

Denisa D Wagner

http://www.w3.org/2001/XMLSchema#string

Guido Stoll

http://www.w3.org/2001/XMLSchema#string

Simon F De Meyer

http://www.w3.org/2001/XMLSchema#string

P2860

High von Willebrand Factor Levels Increase the Risk of First Ischemic Stroke: Influence of ADAMTS13, Inflammation, and Genetic Variability

Anticoagulants for acute ischaemic stroke

Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation

Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

Guidelines for the Early Management of Adults With Ischemic Stroke

A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis

Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke

Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates.

P304

599-606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/STROKEAHA.111.628867

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P50

Christoph Kleinschnitz

P577

2011-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51898804

http://www.w3.org/2001/XMLSchema#string

P698

22180250

http://www.w3.org/2001/XMLSchema#string

P932

4102321

http://www.w3.org/2001/XMLSchema#string